Journal Watch · Frontiers in Immunology · 2026

Two cases of probable Neuro-Behçet syndrome treated with autologous HSCT.

Further studies are required to optimize therapeutic strategies for NBS.

Schubert C, Walter LI, Herwerth M et al.Frontiers in Immunology3 min readPharma relevance 65/100

DOI: 10.3389/fimmu.2026.1864802PMID: 42516391Study type: clinical study

TL;DR

Further studies are required to optimize therapeutic strategies for NBS.

Key findings

  • In summary, NBS or probable NBS should be considered in patients with myelitis and brainstem involvement with limited treatment response.
  • These cases illustrate diagnostic challenges and limitations of current diagnostic criteria, while also underscoring the heterogeneity of disease presentation.
  • Immune reset by aHSCT failed to confer clinical benefit as a rescue therapy in these two patients.
  • Further studies are required to optimize therapeutic strategies for NBS.

What they did

Here, we report the clinical course, treatment strategies and responses of two cases with probable NBS. Both cases presented with longitudinally extensive transverse myelitis and brainstem lesions and experienced recurrent relapses as well as disease progression resistant to multiple immunotherapies. Autologous hematopoietic stem cell transplantation (aHSCT) was without beneficial effect on the disease course in both cases.

Full abstract (original)

Background: Neuro-Behçet syndrome (NBS) is a rare but detrimental neurological manifestation of the Behçet syndrome (BS) - a chronic multisystemic inflammatory disease. NBS is frequently associated with brainstem and spinal cord lesions, often resulting in substantial neurological disability. Atypical clinical presentations can pose significant challenges for diagnosis and treatment of NBS.

What they did: Here, we report the clinical course, treatment strategies and responses of two cases with probable NBS. Both cases presented with longitudinally extensive transverse myelitis and brainstem lesions and experienced recurrent relapses as well as disease progression resistant to multiple immunotherapies. Autologous hematopoietic stem cell transplantation (aHSCT) was without beneficial effect on the disease course in both cases.

Results & conclusions: In summary, NBS or probable NBS should be considered in patients with myelitis and brainstem involvement with limited treatment response. These cases illustrate diagnostic challenges and limitations of current diagnostic criteria, while also underscoring the heterogeneity of disease presentation. Immune reset by aHSCT failed to confer clinical benefit as a rescue therapy in these two patients. Further studies are required to optimize therapeutic strategies for NBS.

Abstract © the authors / Frontiers in Immunology (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.3389/fimmu.2026.1864802 · PubMed 42516391.

Why it matters for pharma & biotech

  • Relevant to Immunology teams tracking Frontiers in Immunology for new targets, mechanisms and biomarkers.
  • Because it reports human data, it can inform indication, endpoint and comparator decisions faster than preclinical work.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.

Frequently asked questions

What did this Frontiers in Immunology study find?

Further studies are required to optimize therapeutic strategies for NBS.

What type of study is this?

It is a clinical study, published in Frontiers in Immunology in 2026. Here, we report the clinical course, treatment strategies and responses of two cases with probable NBS.

Where can I read the original paper?

The original is at the publisher via DOI 10.3389/fimmu.2026.1864802. PubMed ID: 42516391. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Schubert C, Walter LI, Herwerth M et al.. Two cases of probable Neuro-Behçet syndrome treated with autologous HSCT.. Frontiers in Immunology (2026). DOI: 10.3389/fimmu.2026.1864802.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/two-cases-of-probable-neuro-behcet-syndrome-treated-with-autologous-hsct-864802/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides